Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

New Topical Treatment for Continued Pain After Shingles

This study has been completed.
Sponsor:
Collaborators:
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
Biomedical Development Corporation
ClinicalTrials.gov Identifier:
NCT00566904
First received: September 10, 2007
Last updated: August 29, 2011
Last verified: August 2011

September 10, 2007
August 29, 2011
September 2006
August 2008   (final data collection date for primary outcome measure)
Latency to analgesia onset and duration of analgesia measures [ Time Frame: Between 8 and 16 hours after treatment application ] [ Designated as safety issue: No ]
Latency to analgesia onset and duration of analgesia measures [ Time Frame: Between 8 to 16 hours after treatment application ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00566904 on ClinicalTrials.gov Archive Site
Skin irritation potential [ Time Frame: Between 8 and 24 hours after treatment application ] [ Designated as safety issue: Yes ]
Skin irritation potential [ Time Frame: Between 8 to 24 hours after treatment application ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
New Topical Treatment for Continued Pain After Shingles
Phase 1 Novel Topical Treatment for Post-herpetic Neuralgia

Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as postherpetic neuralgia. The purpose of this study is to evaluate the effectiveness of a new topical treatment for postherpetic neuralgia in adults.

After an initial infection of chicken pox, the varicella-zoster virus can remain dormant inside nerve cells. Years later, the virus can be reactivated, causing a repeat outbreak called shingles. The first symptom of shingles is usually a burning or tingling pain in one particular location and on one side of the body. This pain can range from mild to severe. Other possible symptoms of shingles include numbness and itching. After several days or 1 week, a rash of fluid-filled blisters similar to chicken pox appears. For most healthy people, a case of shingles heals within a month. However, some people continue to feel pain after the rash and blisters have resolved; this pain is known as postherpetic neuralgia. Current treatments for postherpetic neuralgia include antiviral drugs, steroids, antidepressants, anticonvulsants, and topical products. A new topical treatment consists of a liquid product that is applied directly to the skin to let dry and form a thin, transparent barrier film. In contrast to creams or ointments that can stay in contact with skin for only minutes, this product remains intact on the skin for many hours, providing sustained delivery of a drug or medication while maintaining barrier protection for the skin. The purpose of this study is to evaluate the effectiveness of this new topical treatment for postherpetic neuralgia in adults.

This study will last about 3 weeks and will include seven study visits on Days 1, 8, 9, 15, 16, 22, and 23. All study visits will include questionnaires on pain levels and an examination and digital photos of the affected skin area. The study visit on Day 1 will also include a urine pregnancy test and a review of medical and medication history. During the study visits on Days 8, 15, and 22, one of three topical products will be applied to participants' affected skin. The product will dry on the skin in 30 to 45 seconds. Participants will then wait at the study site for 1.5 hours, after which they will record the time when they experienced pain relief. At each of these three treatment visits, participants will receive one of the following three topical products: Epikeia coatings with aspirin, Epikeia coatings with local anesthetic, and Epikeia coatings alone. At these three study visits, questionnaires, examinations, and digital photographs will occur both before and after the products are applied to the skin. Throughout the study, participants will record their pain levels and medications in a diary, which will be reviewed at all study visits.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Postherpetic Neuralgia
  • Drug: Epikeia coatings with aspirin
    Applied to affected skin area using a roll-on ball applicator
    Other Name: Epikeia coatings with acetylsalicylic acid
  • Drug: Epikeia coatings with lidocaine
    Applied to affected skin area using a roll-on ball applicator
    Other Name: Epikeia coatings with local anesthetic
  • Other: Epikeia coatings alone
    Applied to affected skin area using a roll-on ball applicator
Experimental: 1
Participants will receive one of three different topical treatments on Days 8, 15, or 22.
Interventions:
  • Drug: Epikeia coatings with aspirin
  • Drug: Epikeia coatings with lidocaine
  • Other: Epikeia coatings alone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
September 2008
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • In good general health
  • Postherpetic neuralgia, defined as pain persisting more than 4 months after onset of herpes zoster outbreak
  • Willing to use effective forms of contraception for the duration of the study

Exclusion Criteria:

  • Known lidocaine sensitivity or allergy
  • Inability to discontinue use of any nonstudy lidocaine-containing products for the duration of the study
  • Known hypersensitivity to aspirin
  • Open herpes zoster blisters
  • Known sensitivity or allergy to an amide-type local anesthetic agent
  • Existing conditions that make participation unsafe
  • Pregnant
  • Immunocompromised (e.g., HIV infected)
  • Herpes zoster in any dermatome (area of skin innervated by a specific sensory nerve) affecting the face or scalp
  • Affected skin area is greater than 420 square cm
  • Affected area includes skin breakdown or nonintact skin
  • Affected area consists of more than one contiguous area
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00566904
R43 AR052998, 1R43AR052998-01, HSC-MS-06-0352
Yes
Biomedical Development Corporation
Biomedical Development Corporation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • The University of Texas Health Science Center, Houston
Principal Investigator: Adelaide A. Hebert, MD The University of Texas Health Science Center, Houston
Biomedical Development Corporation
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP